chr2-44280876-TG-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000341.4(SLC3A1):βc.592delβ(p.Ala198GlnfsTer8) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000409 in 1,614,016 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00024 ( 0 hom., cov: 31)
Exomes π: 0.000020 ( 0 hom. )
Consequence
SLC3A1
NM_000341.4 frameshift
NM_000341.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.10
Genes affected
SLC3A1 (HGNC:11025): (solute carrier family 3 member 1) This gene encodes a type II membrane glycoprotein which is one of the components of the renal amino acid transporter which transports neutral and basic amino acids in the renal tubule and intestinal tract. Mutations and deletions in this gene are associated with cystinuria. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 2-44280876-TG-T is Pathogenic according to our data. Variant chr2-44280876-TG-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 548674.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC3A1 | NM_000341.4 | c.592del | p.Ala198GlnfsTer8 | frameshift_variant | 2/10 | ENST00000260649.11 | NP_000332.2 | |
SLC3A1 | XM_011533047.4 | c.592del | p.Ala198GlnfsTer8 | frameshift_variant | 2/10 | XP_011531349.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC3A1 | ENST00000260649.11 | c.592del | p.Ala198GlnfsTer8 | frameshift_variant | 2/10 | 1 | NM_000341.4 | ENSP00000260649 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000243 AC: 37AN: 152214Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
37
AN:
152214
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000676 AC: 17AN: 251450Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135900
GnomAD3 exomes
AF:
AC:
17
AN:
251450
Hom.:
AF XY:
AC XY:
7
AN XY:
135900
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461802Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 727210
GnomAD4 exome
AF:
AC:
29
AN:
1461802
Hom.:
Cov.:
31
AF XY:
AC XY:
12
AN XY:
727210
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000243 AC: 37AN: 152214Hom.: 0 Cov.: 31 AF XY: 0.000242 AC XY: 18AN XY: 74350
GnomAD4 genome
AF:
AC:
37
AN:
152214
Hom.:
Cov.:
31
AF XY:
AC XY:
18
AN XY:
74350
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cystinuria Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 31, 2023 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 548674). This premature translational stop signal has been observed in individuals with cystinuria (PMID: 18947684, 28646536, 33262960). This variant is present in population databases (rs778000327, gnomAD 0.09%). This sequence change creates a premature translational stop signal (p.Ala198Glnfs*8) in the SLC3A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC3A1 are known to be pathogenic (PMID: 24610330, 25109415, 25964309). - |
Pathogenic, criteria provided, single submitter | clinical testing | College of Medicine Research Centre, King Saud Univeristy | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 30, 2022 | - - |
Nephrocalcinosis;C0392525:Nephrolithiasis Pathogenic:1
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Sep 08, 2017 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 20, 2024 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25964309, 24610330, 28893421, 18947684, 28646536, 25109415, 33262960) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at